Drug intelligence / Profile preview

SJT-SM-SoftMining-NASH

Development stage: Preclinical
Lead developer: SoftMining
Modality: Small Molecules

Overview

SJT-SM-SoftMining-NASH is a preclinical drug candidate being developed by SoftMining for the treatment of non-alcoholic steatohepatitis (NASH). The compound was identified and optimized using SoftMining's proprietary artificial intelligence and computational chemistry platform, which specializes in molecular docking and virtual screening. The project appears to be a collaboration between SoftMining and SJT Molecular Research. As of early 2024, the drug is in the discovery or early preclinical stage, and specific details regarding its molecular target, mechanism of action, and chemical structure have not been publicly disclosed by the developers.

Targets

HTR2A (Serotonin receptor 5-HT2A)FXR (Farnesoid x-activated receptor)

Beyond the preview

Go deeper on SJT-SM-SoftMining-NASH.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SJT-SM-SoftMining-NASH.

Explore the full profile